NASDAQ:CMMB - Nasdaq - US16385C1045 - ADR - Currency: USD
1.25
-0.23 (-15.54%)
The current stock price of CMMB is 1.25 USD. In the past month the price decreased by -40.19%. In the past year, price increased by 61.29%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. The firm specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
CHEMOMAB THERAPEUTICS LTD
Kiryat Atidim, Building 7
TEL AVIV-YAFO 02139 IL
CEO: Neil Cohen
Employees: 20
Company Website: https://www.chemomab.com/
Investor Relations: https://investors.chemomab.com/
Phone: 972773310156
The current stock price of CMMB is 1.25 USD. The price decreased by -15.54% in the last trading session.
The exchange symbol of CHEMOMAB THERAPEUTICS LTD is CMMB and it is listed on the Nasdaq exchange.
CMMB stock is listed on the Nasdaq exchange.
9 analysts have analysed CMMB and the average price target is 9.18 USD. This implies a price increase of 634.4% is expected in the next year compared to the current price of 1.25. Check the CHEMOMAB THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CHEMOMAB THERAPEUTICS LTD (CMMB) has a market capitalization of 23.57M USD. This makes CMMB a Nano Cap stock.
CHEMOMAB THERAPEUTICS LTD (CMMB) currently has 20 employees.
CHEMOMAB THERAPEUTICS LTD (CMMB) has a resistance level at 1.71. Check the full technical report for a detailed analysis of CMMB support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CMMB does not pay a dividend.
CHEMOMAB THERAPEUTICS LTD (CMMB) will report earnings on 2025-05-07.
CHEMOMAB THERAPEUTICS LTD (CMMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).
The outstanding short interest for CHEMOMAB THERAPEUTICS LTD (CMMB) is 4.14% of its float. Check the ownership tab for more information on the CMMB short interest.
ChartMill assigns a technical rating of 2 / 10 to CMMB. When comparing the yearly performance of all stocks, CMMB is one of the better performing stocks in the market, outperforming 89.35% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to CMMB. While CMMB seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months CMMB reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 97.84% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -68.9% | ||
ROE | -88.24% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to CMMB. The Buy consensus is the average rating of analysts ratings from 9 analysts.